Drug Profile


Alternative Names: COTI-2

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Outcome Technologies
  • Developer Critical Outcome Technologies; Northwestern University; University of Texas M. D. Anderson Cancer Center
  • Class Small molecules; Thiosemicarbazones
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Proto oncogene protein c-akt inhibitors; Thymidylate synthase modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cervical cancer; Endometrial cancer; Head and neck cancer; Ovarian cancer
  • Preclinical Acute myeloid leukaemia; Li-Fraumeni syndrome
  • Research Colorectal cancer
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
  • 16 Mar 2017 Critical Outcome Technologies plans a p53 basket trial in Colorectal cancer, Lung cancer and Pancreatic cancer in 2H 2017
  • 17 Feb 2016 Critical Outcome Technologies plans a phase I trial for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top